[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-cancer-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-cancer-pain":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100630588","early-phase-1-hydromorphone-with-electroacupuncture-and-ear-acupoint-pressing-for-refractory-cancer-pain-100630588",false,"NCT07489625","Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain","Observation on the Clinical Efficacy of Hydromorphone Hydrochloride Sustained-Release Tablets Combined With Electroacupuncture and Ear Acupoint Pressing Beans in the Treatment of Refractory Cancer Pain","Inclusion Criteria:\n\n1. Patients who meet the diagnostic criteria for cancer ;\n2. Diagnosis of refractory cancer pain;\n3. Aged 18 or 80 years;\n4. Expected survival period ≥3 months;\n5. Karnofsky Performance Status (KPS) score ≥30 and Quality of Life (QOL) score ≥20;\n6. No history of allergy to opioid analgesics;\n7. No intellectual or psychiatric disorders; normal comprehension ability,capable of cooperating with pain assessments and questionnaire completion;\n8. Provision of signed written informed consent.\n\nExclusion Criteria:\n\n1. Patients with pain clearly unrelated to the tumor itself;\n2. Patients with pain relief after standardized pharmacological treatment;\n3. Patients aged under 18 years or over 80 years;\n4. Patients with an expected survival of less than 3 months;\n5. Patients with a Karnofsky Performance Status (KPS) score \\\u003C 30 or Quality of Life (QOL) score \\\u003C 20;\n6. Pregnant or lactating women;\n7. Patients with intellectual disability, mental or consciousness disturbance, who are unable to assess pain accurately or complete questionnaire surveys;\n8. Patients with needle phobia or extreme resistance to acupuncture treatment;\n9. Patients with hypersensitivity to Semen Vaccariae (Wang Bu Liu Xing).","ALL","18 Years","80 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This trial aims to address refractory cancer pain (RCP). It will explore the synergistic efficacy and safety of hydromorphone hydrochloride sustained-release tablets (HHST) combined with electroacupuncture (EA) and ear acupoint pressing beans (EAPB) for RCP. Key outcomes will include dynamic changes in Numerical Rating Scale (NRS) scores, proportions of patients with effective analgesia (≥30% NRS reduction from baseline) and marked remission (≥50% NRS reduction from baseline), daily HHST dosage, breakthrough pain (BP) frequency, and drug-related adverse events (AEs) graded by CTCAE 6.0.",[27,28],"Refractory Cancer Pain","Cancer Pain",[30,31,32,33,34],"electroacupuncture","ear acupoint pressing beans","hydromorphone","refractory cancer pain","cancer pain","RECRUITING","2026-08-12",{"date":38,"type":39},"2026-08-14","ACTUAL",{"date":41,"type":39},"2026-08-05",{"date":43,"type":21},"2028-12-31",{"name":45,"class":46},"Qinghai Red Cross Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100646266","intrathecal-therapy-versus-standard-care-for-severe-cancer-pain-100646266","NCT07691840","Intrathecal Therapy Versus Standard Care for Severe Cancer Pain","Intrathecal Drug Delivery Systems Versus Comprehensive Medical Management for Severe Cancer Pain: a Randomized Controlled Trial","CAREGIVER","Inclusion Criteria:\n\n* Adult patients (≥18 years) with severe cancer refractory pain (all types of cancer), who have been receiving treatment with oral\u002Fsystemic opioids for at least 4 weeks, and are expected to remain on opioids for the entire duration of the study. More than one opioid rotation has to be done before defining pain refractoriness.\n* Intrathecal therapy is recommended because of inefficacy or intolerance to strong systemic opioid treatment. Inefficacy is defined as mean daily visual analogue scale (VAS) pain intensity score at rest of ≥ 50 mm. Intolerance is defined as the occurrence of (S)AEs (even with dosage less than 200 mg\u002Fday of oral morphine equivalents) which prevents a further increase in the opioid dosage to obtain pain relief.\n* Patients suitable for IDD and with the ability to comply with the medical protocol and visits.\n* Survival prognosis of ≥ 6 months.\n\nExclusion Criteria:\n\n* Patients with active, severe infection.\n* Patients with known brain metastases.\n* Patients with high risk of hemorrhaging.\n* Patients with respiratory depression (for use of morphine).\n* Patients with severe respiratory compromise; baseline oxygen SpO2 \\\u003C 90%, chronic CO2 retention.\n* Patients with severe cardiac disease or risk of cardiotoxicity (for use of bupivacaine).\n* Patients with severe liver impairment or liver failure (for use of ropivacaine).\n* Patients with allergies for medication or IDD hardware.\n* Pregnant or lactating women.\n* Women who plan to become pregnant within 1 month after the study.",{"count":57,"type":21},72,[59],"NA","Approximately 66% of patients with advanced cancer experience pain, which is often inadequately controlled and associated with a decline in health-related quality of life (HRQoL). Conventional pharmacologic management, ranging from simple analgesics to strong opioids, is frequently limited by insufficient efficacy and systemic side effects. Intrathecal drug delivery (IDD) offers targeted, continuous medication infusion directly into the intrathecal space, allowing lower systemic doses and potentially reducing side effects while maintaining effective analgesia. The CAREGIVER study is a randomized, controlled trial designed to evaluate whether patients with severe refractory cancer pain receiving IDD experience a difference in HRQoL compared to those receiving conventional medical management (CMM) with oral pain medications.",[62,27,63],"Intrathecal Drug Delivery","Conventional Medical Management",[65,66,67,68,69],"Intrathecal pumps","Intrathecal drug delivery","Refractory cancer pain","Health-related quality of life","Neuromodulation","2026-07-07",{"date":72,"type":39},"2026-07-09",{"date":74,"type":21},"2026-07-01",{"date":76,"type":21},"2029-10-31",{"name":78,"class":46},"Universitair Ziekenhuis Brussel"]